

Applicants: Ann Marie Schmidt, et al.
U.S. Serial No.: 10/783,635
Filed: February 20, 2004
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1-48. (Cancelled)

49. (Currently Amended) A method for treating a subject suffering from kidney failure, ~~systemic lupus erythematosus, inflammatory lupus nephritis~~ or amyloidoses, which comprises administering to the subject an amount of quinine or quinidine effective to inhibit the interaction between the AGE and RAGE in the subject, so as to thereby treat the subject.

50-57. (Cancelled)

58. (Previously Presented) The method of claim 49, wherein the subject is a human, a primate, an equine subject, an opine subject, an avian subject, a bovine subject, a porcine subject, a canine subject, a feline subject, or a murine subject.

59. (Previously Presented) The method of claim 49, wherein the administration comprises intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; liposome-mediated delivery; or topical, nasal, oral, ocular or otic delivery.

60. (Previously Presented) The method of claim 49, wherein the compound is administered hourly, daily, weekly, monthly or annually.

Applicants: Ann Marie Schmidt, et al.
U.S. Serial No.: 10/783,635
Filed: February 20, 2004
Page 3

61. (Previously Presented) The method of claim 49, wherein the effective amount of quinine or quinidine comprises from about 0.000001 mg/kg body weight to about 100 mg/kg body weight.
62. (Previously Presented) The method of claim 49, wherein the subject is suffering from kidney failure.
63. (Cancelled)
64. (Cancelled)
65. (Previously Presented) The method of claim 49, wherein the subject is suffering from obesity.
66. (Previously Presented) The method of claim 49, wherein the subject is an aged subject.
67. (Previously Presented) The method of claim 49, wherein the subject is suffering from amyloidoses.
68. (Cancelled)
69. (Previously Presented) The method of claim 49, further comprising administering to the subject a pharmaceutically acceptable carrier during the administration of the compound.
70. (Previously Presented) The method of claim 69, wherein the carrier comprises a diluent.

Applicants: Ann Marie Schmidt, et al.
U.S. Serial No.: 10/783,635
Filed: February 20, 2004
Page 4

71. (Previously Presented) The method of claim 69, wherein the carrier comprises a virus, a liposome, a microencapsule, a polymer encapsulated cell or a retroviral vector.
72. (Previously Presented) The method of claim 69, wherein the carrier is an aerosol, intravenous, oral or topical carrier.
73. (Previously Presented) The method of claim 69, wherein the compound is administered from a time release implant.
- 74-76. (Cancelled)
77. (Previously Presented) The method of claim 49, which comprises administering to the subject an amount of quinine.
78. (Previously Presented) The method of claim 49, which comprises administering to the subject an amount of quinidine.